A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation
Study Status
Open to Enrollment
Study Description
This clinical trial is for men and women with advanced hematologic malignancies. The study is evaluating an experimental drug called AG-221.
Participants will take AG-221 twice daily on every day of 28 day cycles. Participants will continue on study treatment for as long as they are responding to therapy and not experiencing unacceptable side effects.
Disease Status and/or Stage
Advanced hematologic malignancies
Sponsor
Agios Pharmaceuticals
Key Eligibility
- Men and women age 18 and older
- Advanced hematologic malignancy, including: Relapsed and/or primary refractory acute myeloid leukemia (AML); Untreated AML in men and women age 60 and older; Myelodysplastic syndrome (MDS)
- IDH2 gene mutation (testing done at screening)
- Detailed eligibility reviewed when you contact the study team
- Yulia Dault
- (212) 746.4829
- [email protected]
Contact
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Erica Bersin
Tel: (646) 962-8232
[email protected]